Update shared on04 Aug 2025
Fair value Increased 2.86%The upward revision in EQL Pharma’s price target reflects higher future P/E expectations despite stable profitability, indicating improved market confidence and raising the consensus fair value from SEK87.50 to SEK95.00.
What's in the News
- EQL is expanding into Germany and the Netherlands by recruiting local experts to launch niche generics, aiming to replicate its Nordic strategy, with plans for future expansion into DACH and BeNeLux regions.
- Memprex, EQL's methenamine hippurate product, has been exclusively licensed to Goodlife Specialty BV for sale in BeNeLux, where there is currently no competing product; milestone payments are tied to agreed sales.
- Marketing approval for EQL's methenamine hippurate product (Altaromin) has been obtained in France, with a launch planned for early 2026, making it the only product of its kind registered in the country.
- EQL forecasts full year 2025/26 sales growth of approximately 30%.
Valuation Changes
Summary of Valuation Changes for EQL Pharma
- The Consensus Analyst Price Target has risen from SEK87.50 to SEK95.00.
- The Future P/E for EQL Pharma has risen from 23.26x to 25.45x.
- The Net Profit Margin for EQL Pharma remained effectively unchanged, moving only marginally from 15.31% to 15.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.